Acute Migraine Treatment Top Companies-Recent Developments, Business Strategy, Deal Strategy, Patent Strategy, Benchmarking and Management Outlook

Acute Migraine Treatment Market Size Analysis and Top Companies

The global acute migraine treatment market size is calculated at  and is projected to hit around USD 9.20 billion by 2033 from USD 3.10 billion in 2023 with a CAGR of 11.30%. The top companies players operating in the acute migraine treatment are Teva Pharmaceutical, Hoffmann-La Roche Ltd., Johnson and Johnson, Amgen, AstraZeneca, Pfizer Inc., Merck & Co., Novartis AG, Eli Lilly & Company, and Others.

Market Report Coverage

Acute Migraine Treatment Key Players 

• Teva Pharmaceutical
• Hoffmann-La Roche Ltd.
• Johnson and Johnson
• Amgen
• AstraZeneca
• Pfizer Inc.
• Merck & Co.
• Novartis AG
• Eli Lilly & Company

Recent Developments

• In January 2022, Elyxyb (celecoxib oral solution) is fast acting liquid drug launched by the BioDelivery sciences. It was the first oral solution which is approved by the Food and Drug Administration (FDA). It's one of a kind ready to use oral solution tailored for adults suffering from severe acute migraine diseases.
• In February 2022, Rimegepant, an orally dissolving tablet, was authorized by the CHMP association (committee for medicinal products for human use) for market use. It is recommended that it be used with a 75mg dose for acute migraine treatment.

We have prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344